Clinical Trial

A Study of KC1036 in Patients with Advanced Thymic Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 17, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-05; most recent amendment 2024-10-15.
Status change: Not Yet Recruiting → Recruiting 2023-03-07
Trial Details
NCT Number NCT05683886
Lead Sponsor Beijing Konruns Pharmaceutical Co., Ltd.
Conditions Thymic Tumors
Enrollment 30 participants
Start Date 2023-02-22
Primary Completion 2025-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2024-10-17